A recent study conducted in Shanghai has demonstrated that the Quality of Life Questionnaire (QLQ-C30) effectively forecasts mortality rates among community-based cancer patients. This research highlights the significant role that patient-reported outcomes play in understanding and predicting cancer survival.
Comprehensive Study Design
Researchers employed a whole-cluster sampling method to enroll 3,304 cancer patients from four communities in Shanghai between 2018 and 2019. Participants completed a detailed questionnaire that captured demographic information, cancer types, and responses to the QLQ-C30 scale. Follow-up data on mortality were meticulously gathered from local community health care centers up until 2023.
Significant Findings
The analysis revealed that patients who survived had a higher average QLQ-C30 total score (92.96) compared to those who deceased (85.21), with the difference being statistically significant (p < 0.001). Additionally, scores across five specific dimensions and the overall utility score were consistently higher among survivors. Cox regression models, adjusted for various covariates, confirmed that elevated QLQ-C30 scores correlate with a reduced risk of death. Specifically, the hazard ratio was 0.81 for the total score, ranging from 0.83 to 0.89 for the dimension scores, and 0.83 for the utility score, all with p < 0.001.
- Higher QLQ-C30 scores significantly lower mortality risk in cancer patients.
- Comprehensive quality of life assessments can enhance prognostic models.
- Community-based approaches provide valuable insights into patient outcomes.
The study underscores the utility of the QLQ-C30 as a reliable tool for predicting all-cause mortality among Chinese cancer patients. By integrating quality of life metrics into patient assessments, healthcare providers can identify high-risk individuals and tailor interventions more effectively.
Healthcare professionals and policymakers should consider incorporating QLQ-C30 assessments into routine cancer care to improve survival outcomes. Additionally, further research could explore the application of this tool in different regions and among diverse patient populations to validate its predictive power globally.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
